



SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June 09, 2025

PROPOSAL

Re: Approval of the 2024 Audited Financial Statements

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company, audited by AASC Auditing Firm Company Limited.

The Board of Directors respectfully submits to the General Meeting of Shareholders of the Company for consideration and approval the following matter:

In accordance with the Resolution of the 2024 Annual General Meeting of Shareholders regarding the selection of an independent auditing firm for the 2024 financial statements, the Company appointed AASC Auditing Firm Company Limited to conduct the independent audit of the 2024 financial statements.

The Company's 2024 financial statements were independently audited by AASC Auditing Firm Company Limited, with the audit report signed on March 21, 2025.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Company Shareholders;
- BOD; BOM;
- BOS;
- Archived: Company Secretary.

**ON BEHALF OF
THE BOARD OF DIRECTORS**

Thái Khắc Minh



No.: 02/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 09, 2025

PROPOSAL

Re: Selection of the Independent Auditor for the 2025 Financial Statements

To: The General Meeting of Shareholders

of Mediplantex National Pharmaceutical Joint Stock Company

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;
- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company.

The Board of Supervisors of Mediplantex National Pharmaceutical Joint Stock Company respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

In order to ensure proactivity in selecting an appropriate auditing firm that meets the Company's requirements regarding the timing and quality of auditing services for the financial statements of the fiscal year 2025, the Board of Supervisors respectfully proposes that the General Meeting of Shareholders consider and approve the following content:

1. Approval of the following list of five (05) auditing firms as candidates to perform the audit of the financial statements for the fiscal year 2025 and to conduct reviews of the quarterly and semi-annual financial statements (if required by State regulatory authorities) for Mediplantex National Pharmaceutical Joint Stock Company.
 - 1.1. KPMG Company Limited;
 - 1.2. AASC Auditing Firm Company Limited;
 - 1.3. PWC (Vietnam) Company Limited;
 - 1.4. Viet Nam Auditing & Evaluation Company Limited;
 - 1.5. An Viet Auditing Company Limited.
2. Estimated auditing fee: From VND 200,000,000 to VND 500,000,000.
3. Authorization for the General Director to sign the audit contract with the auditing firm proposed and selected by the Board of Supervisors.

Respectfully submits to the General Meeting of Shareholders for consideration and approval.

Recipients:

- Company Shareholders;
- BOD; BOM;
- BOS;
- Archived: Company Secretary.

**ON BEHALF OF
THE BOARD OF SUPERVISORS
HEAD**

Ho Ngoc Tuan



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Quận Thanh Xuân - Hà Nội

Website: <http://www.mediplantex.com>

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 09, 2025

PROPOSAL

No: 03/2025/TTr-DHDCD



Re: Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

Pursuant to:

- Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;
- Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, , effective as of January 1, 2021, and amended by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024;
- The charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- The 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2024 business and production results and the implementation plan for 2025.

The Board of Directors respectfully submits to the General Meeting of Shareholders for consideration and approval the following matter:

I. PROFIT DISTRIBUTION PLAN FOR 2024:

Indicators	Percentage (%)	Year 2024 (Unit: VND)
1. Profit before tax in 2024		19,418,107,894

2. Corporate income tax payable in 2024		4,171,341,682
3. Profit after tax in 2024		15,246,766,212
4. Profit distribution in 2024		15,246,766,212
4.1. Bonus allocation to the Board of Management		246,584,856
<i>Bonus for achieving profit plan</i>	<i>1 %</i>	<i>128,938,363</i>
<i>Additional bonus of 05% of profit value exceeding plan</i>		<i>117,646,493</i>
4.2. Bonus allocation to the Board of Directors and the Board of Supervisors	<i>1%</i>	246.584.856
<i>Bonus for achieving profit plan</i>		<i>128.938.363</i>
<i>Additional bonus of 05% of profit value exceeding plan</i>		<i>117.646.493</i>
4.3. Allocation to the Development Investment Fund	0%	
4.4. Remaining profit for dividend distribution		14,753,596,500
5. Retained earnings from previous years		503,923,388
6. Total profit for dividend distribution up to the end of 2024		15,257,519,888
7. Proposed dividend distribution	10% of charter capital	12,410,000,000
8. Retained earnings carried forward to 2025		2,847,519,888

II. PLAN TO ISSUE SHARES TO PAY DIVIDENDS IN 2024

The plan to issue shares to pay dividends in 2024 is as follows:

1. Stock: Shares of Mediplantex National Pharmaceutical Joint Stock Company
2. Share status before issuance:
 - Number of shares: 12,410,000 shares;
 - Share type: Common shares;
 - Par value: VND 10,000/share.
3. Par value: VND 10,000/share.
4. Type of shares issued: common shares, freely transferable.



5. Number of shares expected to be issued: 1,241,000 shares.
6. Total value according to par value of shares expected to be issued: VND 12,410,000,000.
7. Number of shares expected after issuance: 13,651,000 shares.
8. Expected charter capital after issuance: VND 136,510,000,000.
9. Issuance purpose: to pay dividends in 2024.
10. Issuance subjects: Existing shareholders whose names are on the shareholder list as determined by the Vietnam Securities Depository and Clearing Corporation on the last registration date to exercise the right to purchase shares.
11. Issuance ratio: 10:1 (Shareholders owning 10 shares on the record date are entitled to receive 01 additional newly issued share).
12. Issuance capital source: Undistributed profit after tax determined as of December 31, 2024 on the audited Financial Statements.
13. Plan for handling fractional shares: Shares issued to existing shareholders will be rounded down to the nearest unit. Any arising fractional shares will be canceled.
For example: Shareholder A owns 166 shares on the shareholder record date, with the right exercise ratio of 10:1, shareholder A will receive $(166/10) = 16.6$ new shares. According to the above rounding principle, shareholder A will receive 16 new shares, the decimal part of 0.6 shares will be canceled.
14. Expected issuance time: immediately after approval from the State Securities Commission. Expected in the third quarter of 2025

III. PROPOSAL FOR 2025

- Based on the 2025 business and production plan of Mediplantex National Pharmaceutical Joint Stock Company, the Board of Directors proposes the allocation of bonuses and the dividend payout rate for 2025 as follows:

Projected for 2025	Percentage %	Amount VND
I. Profit Before Tax 2025		21,100,473,362
II. Profit After Tax 2025		15,825,355,022
1. Allocation for bonus to the Board of Management	1%	158,253,550
2. Allocation for bonus to the Board of Directors and the Board of Supervisors	1%	158,253,550
3. Allocation to the Development Investment Fund	0	



4. Expected dividend profit after implementing the plan to issue shares to pay dividends in 2024	10% of charter capital	13,651,000,000
5. Retained earnings 2026		1,857,847,922

- The allocation of bonuses to the Board of Management, Board of Directors and the Board of Supervisors at the above-mentioned rates shall only be implemented if the profit after tax in 2025 reaches 90% to 100% of the 2024 approved plan.
- In the event that the 2025 performance exceeds the plan approved by the General Meeting of Shareholders:
 - + Additional bonus for the Board of Management at the rate of 05% of the excess amount over the plan.
 - + Additional bonus for the Board of Directors and the Board of Supervisors at the rate of 05% of the excess amount over the plan.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, BOM, Company Secretary
- Archived: Office, BOD.

**ON BEHALF OF
THE BOARD OF DIRECTORS**



Thái Khắc Minh



CÔNG TY CỔ PHẦN DƯỢC TRUNG ƯƠNG MEDIPLANTEX

Địa chỉ: 358 Đường Giải Phóng - Quận Thanh Xuân - Hà Nội

Website: <http://www.mediplantex.com>

No.: 04/2025/TTr-DHDCD

SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 09, 2025

PROPOSAL

Re: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, effective as of January 1, 2021, and amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the 2024 financial statements of Mediplantex National Pharmaceutical Joint Stock Company audited by AASC Auditing Firm Company Limited;
- The 2024 business and production results and the implementation plan for 2025.

The Board of Directors respectfully submits to the General Meeting of Shareholders the following matter for consideration and approval:

In regard to the activities of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2024, the Company hereby reports the remuneration levels of each member of the Board of Directors and the Board of Supervisors for the year 2024:

❖ **Remuneration of Each Member of the Board of Directors and the Board of Supervisors in 2024:** *has been detailed in the audited financial statements for 2024.*

No.	Items	Amount (VND)
1	Unpaid remuneration of the Board of Directors of the previous year carried forward	0
2	Remuneration of the Board of Directors in 2024	646,000,000
2.1	Board of Directors' remuneration deducted in 2024	418,000,000



2.2	Remaining Board of Directors' remuneration carried forward to 2025	228,000,000
3	Remuneration of the Board of Supervisors, in 2024	204,000,000
3.1	Board of Supervisors and Secretary's remuneration deducted in 2024	152,000,000
3.2	Remaining Board of Supervisors and Secretary's remuneration carried forward to 2025	52,000,000

Other entitlements of the members of the Board of Directors and the Board of Management shall be implemented in accordance with the provisions of law, the Company's Charter, and internal regulations.

❖ **Proposed Remuneration for 2025:**

To ensure the effective operation of the Board of Directors and the Board of Supervisors in carrying out their assigned duties in 2025, and based on the business plan of Mediplantex National Pharmaceutical Joint Stock Company for 2025, as well as relevant regulations of the State, the Company's Charter, and internal regulations, the Board of Directors respectfully submits for approval the proposed total remuneration for 2025:

Remuneration	Amount
Member of the Board of Directors	646,000,000
Member of the Board of Supervisors and Secretary	204,000,000
Total	850,000,000

Respectfully submits to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- Shareholders of Mediplantex National Pharmaceutical Joint Stock Company;
- BOD, BOS, Company Secretary
- Archived: Office, BOD.

ON BEHALF OF
THE BOARD OF DIRECTORS



Thai Khắc Minh



SOCIALIST REPUBLIC OF VIETNAM

Independence – Freedom – Happiness

Hanoi, June 09, 2025

PROPOSAL

**Rec Approval of the Election for the Additional Member of the Board of Directors
for the 2024 – 2029 Term**

**To: The General Meeting of Shareholders
of Mediplantex National Pharmaceutical Joint Stock Company**

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, as amended by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022;

- Pursuant to the Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;

- Pursuant to the Regulation on the Operation of the Board of Directors of the Company;

The Board of Directors (BOD) respectfully submits to the General Meeting of Shareholders for consideration and approval the election of an additional member to the BOD for the 2024–2029 term, as follows:

- Number of additional members to be elected to the BOD: 01 member
- Criteria for selecting a member of the BOD: In accordance with Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulations on the Operation of the BOD.
- Number of candidates: Unlimited.

Based on the nomination and self-nomination results submitted by shareholders and groups of shareholders in accordance with the Company's Charter, and considering the competence, qualifications, and reputation of the nominees, and in compliance with the criteria for BOD members as prescribed by the Company's Regulations on the Operation of the BOD and applicable laws, the BOD respectfully submits to the General Meeting of Shareholders for approval the List of Candidates for the election of one (01) additional member of the BOD for the remainder of the 2024 – 2029 term as follows:

- Mr./Ms: Candidate for the Board of Directors

Curricula Vitae of the Candidates Attached to This Proposal.

Respectfully submits to the General Meeting of Shareholders for consideration and approval./

Recipients:

- Company Shareholders;
- BOD; BOS;
- Archived: Company Secretary.

**ON BEHALF OF
THE BOARD OF DIRECTORS**

Thái Khắc Minh



Hanoi, / / 2025

RESOLUTION
2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

Pursuant to:

- Pursuant to the Law on Enterprises No. 59/2020/QH14 adopted by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, and effective from January 1, 2021, as amended by Law No. 03/2022/QH15 adopted by the National Assembly on January 11, 2022;
- Pursuant to the Law on Securities No. 54/2019/QH14 dated November 26, 2019, passed by the National Assembly of the Socialist Republic of Vietnam, as amended by Law No. 56/2024/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its guiding documents;
- Pursuant to the Charter on organization and operation of Mediplantex National Pharmaceutical Joint Stock Company;
- Pursuant to the Minutes of the 2025 Annual General Meeting of Shareholders No. ... dated June 30, 2025;
- Pursuant to the Vote Counting Minutes of the 2024 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company dated June 30, 2025.

The 2025 Annual General Meeting of Shareholders (“AGM”) of Mediplantex National Pharmaceutical Joint Stock Company, convened at Guest House T99, Military Zone of the Capital – No. 99 Le Duan Street, Cua Nam Ward, Hoan Kiem District, Hanoi, on June 30, 2025, hereby adopts the following Resolution:

RESOLUTION

Article 1. Approval of the following reports:

- Report of the Board of Directors on its performance in 2024 and the proposed operational plan for 2025;
- Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025;
- Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025;

- Article 2.** Approval of the audited financial statements for 2024 (*Pursuant to Proposal No. 01/2025/TTr-DHDCD dated ...*).
- Article 3.** Approval of the selection of an independent auditing firm for the 2025 financial statements (*Pursuant to Proposal No 02/2025/TTr-DHDCD dated ...*).
- Article 4.** Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025 (*Pursuant to Proposal No 03/2025/TTr-DHDCD dated ...*).
- Article 5.** Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 (*Pursuant to Proposal No. 04/2025/TTr-DHDCD dated ...*).
- Article 6.** Approval of the Election for the Additional Member of the Board of Directors for the 2024–2029 Term (*Pursuant to Proposal No. 05/2025/TTr-DHDCD dated ...*) for:
- Mr./Ms.:
- Year of birth:
- Professional qualifications:

This Resolution shall take effect from the date of issuance. The Board of Directors, the Board of Supervisors, the Board of Management, and all relevant departments shall be responsible for implementing this Resolution.

**ON BEHALF OF THE 2025 GENERAL MEETING OF SHAREHOLDERS
CHAIRPERSON**



Thai Khắc Minh

Hanoi, June 06, 2025



**WORKING AND VOTING REGULATIONS
OF THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, and its guiding documents;*
- *The Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, as amended and supplemented by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024, and its guiding documents;*
- *The Charter on Organization and Operation issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Internal Regulations on Corporate Governance issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *Resolution of the Board of Directors No. 04/2025/NQ-BOD dated May 09, 2025 of the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company.*

The 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company (“MED” or the “Company”) shall be convened and conducted in accordance with the following Working and Voting Regulations:

Article 1. Purpose

- To ensure that the procedures, principles of conduct, and voting at the Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company are carried out in accordance with regulations and in a successful and orderly manner.
- To ensure that the resolutions of the General Meeting of Shareholders reflect the unified

will of the General Meeting, safeguard the legitimate rights and interests of shareholders, and comply with applicable laws.

Article 2. Scope of Regulation and Subjects of Application

- ***Scope of Regulation:*** These Regulations shall apply to the organization of the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
- ***Subjects of Application:*** All delegates and authorized representatives attending the MED Annual General Meeting of Shareholders must comply with the provisions set forth in these Regulations, the Company's Charter, and the prevailing laws and regulations.

Article 3. Conditions for Convening the General Meeting of Shareholders (*Pursuant to the Company's Charter*)

- The General Meeting of Shareholders (GMS) shall be convened when the attending shareholders represent more than 50% of the total voting shares.
- In the event that the required number of shareholders is not present within thirty (30) minutes from the scheduled opening time of the meeting, a second meeting invitation must be issued within thirty (30) days from the intended date of the first GMS. The reconvened GMS shall only be conducted if the attending shareholders and authorized representatives represent at least 33% of the total voting shares.
- If the second meeting cannot be held due to the absence of the required number of attendees within thirty (30) minutes from the scheduled start, a third meeting invitation must be issued within twenty (20) days from the intended date of the second GMS. In this case, the GMS shall be convened regardless of the number of shareholders or authorized representatives in attendance and shall be deemed valid, with the authority to decide on all matters originally proposed for approval at the first GMS.

Article 4. Delegates Attending the General Meeting of Shareholders

1. All shareholders of MED holding voting shares (according to the shareholder list as of the record date: May 29, 2025) have the right to attend or authorize their representative to attend the General Meeting of Shareholders. In the case of individual shareholders, authorization may only be granted to one other individual. In the case of an organizational shareholder with more than one authorized representative attending the meeting as prescribed by law, the number of shares and voting rights assigned to each representative must be clearly specified. An authorized representative who has received power of attorney to attend the meeting is not permitted to further authorize another person to attend on their behalf.



2. Authorization for an individual or organization to represent and attend the General Meeting of Shareholders must be made in writing. The power of attorney must be prepared in accordance with civil law and must clearly state the name of the authorizing shareholder; the name of the individual or organization authorized; the number of shares authorized; the content and scope of authorization; the duration of authorization; and must be signed by both the authorizing party and the authorized party. The authorized individual or organization must submit the original valid power of attorney to the Company before completing registration procedures for attending the meeting.
3. Shareholders and/or authorized representatives hereinafter referred to as “Delegates” must be present at the meeting venue on time and complete the registration procedures with the Organizing Committee of the Meeting. Upon arrival, Delegates must bring lawful identification documents as prescribed in the Notice of the General Meeting to confirm their delegate status.
4. During registration, the Company shall issue each Delegate a voting card and voting and election ballots (if applicable), on which will be recorded the registration number, full name of the shareholder or authorized representative, and the number of votes or election ballots belonging to that shareholder or authorized representative.
5. During the General Meeting of Shareholders, Delegates must comply with the following regulations:
 - a. Be punctual, wear formal attire, comply with security checks (if any), and present identification documents as required by the Meeting Organizing Committee;
 - b. Receive the meeting dossiers and materials at the delegate reception desk;
 - c. Shareholders or authorized representatives arriving after the meeting has commenced may still register and participate in voting immediately after registration. The Chairperson shall not suspend the meeting for late registrants; in such cases, the validity of votes already conducted shall not be affected;
 - d. Keep mobile phones on silent mode or turned off; any necessary calls should be taken outside the meeting room;
 - e. Comply with regulations issued by the Organizing Committee and the Chairperson of the Meeting;
 - f. The Board of Directors may require shareholders or authorized representatives attending the General Meeting to undergo security inspections or other security measures deemed appropriate by the Board of Directors;
 - g. If any shareholder or authorized representative refuses to comply with security checks or



measures mentioned above, the Board of Directors, after careful consideration, may refuse or remove such shareholder or representative from the Meeting.

Article 5. Presidium

1. The Presidium shall consist of 03 members, including 01 Chairperson and 02 members. The Chairman of the Board of Directors shall serve as the Chairperson of the Presidium and shall be Chairperson of the 2025 Annual General Meeting of Shareholders of MED.
2. In case the Chairperson is absent or temporarily unable to perform duties, the remaining members shall elect one among themselves to act as the Chairperson of the meeting according to the majority rule. In the event that no Chairperson is elected, the Head of the Board of Supervisors shall preside over the process for the General Meeting of Shareholders to elect a Chairperson of the meeting, and the person who receives the highest number of votes shall act as the Chairperson of the meeting.
3. Duties of the Presidium:
 - a. To preside over the activities of the General Meeting of Shareholders in accordance with the Agenda proposed by the Board of Directors and approved by the General Meeting;
 - b. To guide the Delegates and the Meeting in discussing the matters included in the agenda;
 - c. To present draft resolutions and provide conclusions on necessary issues for the General Meeting to vote on;
 - d. To respond to matters requested by the General Meeting;
 - e. To address any issues arising during the course of the Meeting.

4. Working principles of the Presidium:

The Presidium shall operate on the principles of collectivity, democratic centralism, and decision-making by majority vote..

Article 6. Secretariat of the General Meeting

1. The Secretariat of the General Meeting shall consist of 02 members nominated by the Chairperson (through the Organizing Committee of the General Meeting); it shall be accountable to the Presidium and the General Meeting of Shareholders for the fulfillment of its assigned duties and shall operate under the direction of the Presidium.
2. Duties of the Secretariat:
 - a. Assist the Presidium in verifying the qualifications of the attending delegates (when necessary);



- b. Support the Presidium in announcing draft documents, conclusions, and Resolutions of the General Meeting and in delivering notifications from the Presidium to the Delegates upon request;
- c. Receive and review Discussion Slips and delegates' opinions, and forward them to the Presidium for consideration and decision;
- d. Record fully and accurately the entire proceedings of the General Meeting and all approved or noted matters in the Meeting Minutes;
- e. Prepare the Minutes of the Meeting and draft the Resolution on the matters approved at the General Meeting;
- f. Support the Chairperson in disclosing information related to the General Meeting of Shareholders and in notifying the Delegates in accordance with legal regulations and the Company's Charter.

Article 7. Delegates Eligibility Examination Committee

1. The Delegates Eligibility Examination Committee of the General Meeting shall consist of 03 members, including 01 Head and 02 members, established by the Board of Directors and introduced to the General Meeting by the Presidium. The Committee shall be accountable to the Presidium and the General Meeting of Shareholders for the performance of its duties.
2. Duties of the Delegates Eligibility Examination Committee:
 - a. The Committee is responsible for verifying the qualifications and attendance status of shareholders participating in the meeting
 - b. The Head of the Committee shall report to the General Meeting of Shareholders on the status of shareholders in attendance. If the meeting has a sufficient number of delegates representing more than 50% of the total voting shares, the MED General Meeting of Shareholders shall be deemed valid and may proceed.

Article 8. Vote Counting Committee

1. The Vote Counting Committee of the General Meeting shall consist of 03 members, including 01 Head and 02 members, who are nominated by the Chairperson (through the Meeting Organizing Committee) and approved by the General Meeting.
2. Duties of the Vote Counting Committee:
 - a. Disseminate the principles, regulations, and guidelines on the voting procedures;
 - b. Verify and record voting cards, prepare vote counting minutes, announce results; submit the minutes to the Chairperson for approval of voting and election results;
 - c. Promptly notify the Meeting Secretary of the voting results;
 - d. Review and report to the General Meeting any violations of voting regulations or



- complaints regarding the voting results;
- e. Prepare the vote counting minutes and be accountable to the Presidium and the General Meeting of Shareholders in the performance of their duties.

Article 9. Discussion at the General Meeting

1. Principles:

- a. Discussions shall only take place within the prescribed time and within the scope of issues presented in the agenda of the General Meeting of Shareholders;
- b. Delegates wishing to speak must register their topics on the Discussion Sheet and submit it to the Secretariat;
- c. The Secretariat shall organize the Discussion Sheets of the delegates in order of registration and forward them to the Presidium;
- d. Delegates must raise their hand when wishing to speak or debate and may only speak upon approval by the Presidium. Each delegate's speech shall not exceed 5 minutes, and content must be concise and avoid repetition.

2. Response to delegates' opinions:

- a. Based on the delegates' Discussion Sheets, the Chairperson or a member appointed by the Chairperson shall respond to the delegates' opinions;
- b. In cases where time constraints prevent direct responses at the meeting, MED shall provide written answers to the questions after the General Meeting..

Article 10. Voting

1. Principles:

- a. All matters in the agenda and contents of the General Meeting must be openly discussed by the General Meeting of Shareholders and openly voted on either by raising voting cards or by secret ballot using voting slips.
- b. Voting cards and voting slips are printed, sealed with the company's stamp, and directly delivered by MED to delegates at the meeting (attached with the set of documents for attending the General Meeting). Each delegate is issued one voting card and one voting slip. On the voting card and voting slip, the delegate's registration code, full name, number of shares owned and proxy votes authorized to the delegate are clearly indicated.
- c. Forms of voting on matters at the 2025 Annual General Meeting of Shareholders:
 - ***Voting by raising the voting card:*** this form is used to approve matters such as the Meeting agenda; the Working and Voting Regulations at the Meeting; approval of the Vote Counting Committee; approval of the Meeting Minutes, Meeting Resolutions, and other contents at the Meeting (if any);



- ***Voting by filling out the voting ballot:*** this form is used to approve the contents of proposals submitted to the Meeting, as specified and clearly indicated in each voting ballot sent to each shareholder.

2. Voting Method:

- a. Delegates shall cast their vote as “Agree,” “Disagree,” or “Abstain” on each matter put to a vote at the General Meeting by either raising the Voting Card or marking the corresponding options on the Voting Slip in accordance with the provisions of Clause 2 of this Article.
- b. When voting by raising the Voting Card:
 - The front side of the Voting Card must be held up facing the Presidium.
 - In the event that a delegate does not raise the Voting Card during any of the three voting rounds (“Agree,” “Disagree,” or “Abstain”) on a matter, it shall be deemed as a vote in favor of that matter.
 - In the event that a delegate raises the Voting Card more than once across the three voting rounds (“Agree,” “Disagree,” or “Abstain”) on a matter, the vote for that matter shall be considered invalid.
 - Under this form of voting, members of the Vote Counting Committee/Delegate Eligibility Verification Committee shall mark the delegate code and corresponding number of votes of each shareholder as “Agree,” “Disagree,” “Abstain,” or Invalid.
- c. When voting by filling out the Voting Ballot:
 - For each item, the delegates shall select one of the three options “Agree,” “Disagree,” or “Abstain,” which are pre-printed on the Voting Ballot, by marking “✕” or “✓” in the box corresponding to their choice.
 - In the case that a delegate or proxy arrives after the Voting Ballot collection has concluded, such delegate may still register and vote on issues arising after their registration, but shall not be permitted to vote on matters for which voting has already been completed. In this case, the validity of previously conducted votes shall remain unaffected.
 - A voting item shall be deemed invalid if the shareholder or authorized representative does not mark any voting box or marks more than one box for the same item. If a Voting Ballot is otherwise valid but contains one or more invalid voting items, the valid votes on the remaining items shall still be counted in the results for those respective items.
 - Upon completing all voting items of the General Meeting, the delegate shall submit the Voting Ballot into the sealed ballot box provided at the meeting, as instructed by the Vote



Counting Committee. The Voting Ballot must bear the delegate's signature and full name.

3. Valid Voting Ballot:

- a. The Ballot must be based on the pre-printed template issued by the Organizing Committee;
- b. It must not contain any erasures, scratching, alterations, tears, or damage, and must not include any additional voting content beyond what is stipulated for the slip.
- c. It must bear the handwritten signature and full name of the attending delegate.
- d. For each item on the Voting Ballot, the vote is considered valid when the delegate marks only one (01) of the three (03) voting options for that item.

4. Invalid Voting Ballot:

- a. The Ballot is not issued by the Organizing Committee;
- b. The Ballot is not signed and does not contain the full handwritten name of the delegate;
- c. The Ballot does not bear MED's official red seal or contains erasures, scratching, alterations, or any additional markings or content beyond what is stipulated for the voting slip;
- d. The Ballot contains only invalid voting items;
- e. The Ballot is submitted after the ballot box has been unsealed.

5. In the event that a delegate requests to exchange a voting ballot due to it being torn, damaged, or inadvertently marked with additional symbols ("damaged voting slip"), and provided that the delegate has not yet cast the vote into the ballot box and the voting period has not expired, the delegate shall have the right to directly approach the Vote Counting Committee to return the damaged voting ballot in exchange for a new one, in order to safeguard shareholder rights. The Vote Counting Committee shall collect all damaged voting slips and submit them to the Presidium.

6. Approval of Resolutions by the General Meeting of Shareholders:

- a. Pursuant to Clause 1, Article 21 of the Company's Charter, a resolution on the following matters shall be passed if it is approved by shareholders representing **at least 65%** of the total voting rights of all shareholders attending and voting at the General Meeting:
 - Amendments and supplements to the Company's Charter;
 - Types of shares and the total number of shares to be offered;
 - Merger, reorganization, and dissolution of the Company;
 - Decisions on investments or transactions involving the sale of assets with a value equal to or greater than 35% of the total asset value recorded in the most recent audited financial



statements of the Company;

- Changes to business sectors, lines, and fields of operation.
- b. Except for the above-mentioned cases, other resolutions shall be approved when voted in favor by shareholders representing more than 50% of the total voting rights of all shareholders attending and voting at the General Meeting, unless otherwise provided in Clause 1, Article 21 of the Company’s Charter and Clauses 3, 4, and 6.

Article 11. Voting for the Additional Election of Members of the Board of Directors (Election):

1. The election of additional members to the Board of Directors for the 2024 – 2029 term shall be conducted by cumulative voting. Accordingly, each shareholder shall have a total number of votes equal to the number of shares they hold multiplied by the number of additional members to be elected to the Board of Directors for the 2024–2029 term. Shareholders may allocate all or part of their total votes to one or more candidates, but the total number of elected candidates must not exceed the number approved by the General Meeting of Shareholders. The elected candidates shall be those who receive the highest number of votes, in descending order, until the number of required members is reached. In the event that two or more candidates receive an equal number of votes for the final seat(s), a re-election shall be conducted among those candidates, or an alternative selection method shall be used based on criteria approved by the General Meeting of Shareholders.

2. Instructions for Completing the Ballot:

- Each ballot for electing members of the Board of Directors may be used to vote for a maximum number of candidates equal to the number of seats approved by the General Meeting of Shareholders.
- Each ballot includes two columns: the “Cumulative Voting” column and the “Number of Votes” column. Shareholders shall cast their votes according to the following instructions:

Case 1: If the shareholder allocates all votes to a single candidate

+ The shareholder shall mark an "X" in the box under the “Cumulative Voting” column corresponding to that candidate.

Case 2: If the shareholder chooses not to vote for any candidate

+ The shareholder shall leave all fields in both the “Cumulative Voting” and “Number of Votes” columns blank for all candidates, without making any marks or annotations.

+ The shareholder or the authorized representative of the shareholder must sign and clearly write their full name on the ballot.

3. Validity and Invalidity of Ballots

- Valid Ballot: A valid ballot must be the official printed form issued by the Organizing Committee, without erasures, alterations, or any additional content beyond the designated



sections. It must bear the signature and clearly printed full name of the attending shareholder or their authorized representative.

- The following ballots shall be considered invalid:
 - + Ballots containing any additional content not specified in the official template;
 - + Ballots filled in using a pencil;
 - + Ballots on which candidate names have been crossed out;
 - + Ballots that are not on the official printed form issued by the Organizing Committee, or that have been erased, altered, or contain added content beyond the ballot’s intended format;
 - + Ballots on which the number of candidates selected exceeds the number of Board of Directors members approved by the General Meeting of Shareholders for the 2024–2029 term;
 - + Ballots submitted after the Ballot Counting Committee has unsealed the ballot box;
 - + Ballots that do not contain the signature of the attending shareholder.

Article 12. Minutes and Resolutions of the General Meeting of Shareholders

The minutes of the meeting and the resolutions of the General Meeting of Shareholders must be read aloud and adopted prior to the closing of the General Meeting.

Article 13. Implementation of the Regulations

All delegates and invited participants attending the General Meeting must strictly comply with these Regulations on working procedures and voting, the current rules, internal regulations, corporate governance provisions of the Company, and all relevant legal regulations. Any delegate who violates these Regulations shall, depending on the severity of the violation, be subject to consideration and appropriate measures by the Presidium in accordance with the Company’s Charter and the Law on Enterprises.

These Regulations comprise 13 Articles and shall take effect immediately upon approval by the 2025 General Meeting of Shareholders of the Company.

ON BEHALF OF THE BOARD OF DIRECTORS

Thái Khắc Minh





MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS



VOTING CARD

VOTER ID:

.....

Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented: votes



**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025**



VOTING BALLOT

VOTER ID:

Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented:votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Approval of Report of the Board of Directors on its performance in 2024 and the proposed operational plan for 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Approval of Report of the Board of Management on the 2024 business and production results and the implementation plan for 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 03: Approval of Report of the Board of Supervisors on its 2024 activities and supervisory work, along with the proposed plan for 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 04: Approval of the audited financial statements for 2024	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 05: Approval of the selection of an independent auditing firm for the 2025 financial statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 06: Approval of the profit distribution plan and dividend payout ratio for 2024, and the proposed profit distribution plan and dividend payout ratio for 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 07: Approval of remuneration for the Board of Directors and the Board of Supervisors for 2025	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 08: - Approval of the Election for the Additional Member of the Board of Directors for the 2024–2029 Term	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Proposal.


June 30th 2025

VOTER

(Signature and full name)



MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
ANNUAL GENERAL MEETING OF SHAREHOLDERS 2025



VOLE ON THE BOARD OF DIRECTORS

VOTER ID:

Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented:votes

Total number of voting rights..... voting rights

I hereby agree to cast the votes for the chosen Additional Member of the Board of Directors

No	Full Name	Cumulative voting	Number of votes
1	...	<input type="checkbox"/>	<input type="text"/>

Guide:

1. The maximum number of candidates that delegates are eligible to elect is equal to the number of candidates needed to elect (01 member)
2. If accumulative elect the entire elect for one or several candidates, delegates mark in “Cumulative voting” of the corresponding candidates.
3. If the number of elections is uneven for many candidates, the delegate must specify the number of elections in the “Number of votes” of the corresponding candidates.

June 30th, 2025

VOTER

(Signature and full name)

Hanoi, June 9th, 2025



**NOTICE OF NOMINATION, SELF-NOMINATION, AND ELECTION
FOR SUPPLEMENTARY MEMBER OF THE BOARD OF DIRECTORS
FOR THE REMAINING 2024 – 2029 TERM**

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, and its guiding documents;*
- *The Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, as amended by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024, and its guiding documents;*
- *The Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Company's Internal Regulation on Corporate Governance, the Operational Regulations of the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company;*

The Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company hereby notifies the esteemed shareholders of the specific regulations regarding the nomination and self-nomination for the election of additional member to the Board of Directors for the remaining 2024 – 2029 term, as follows:

**I. ELECTION ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS
FOR THE REMAINING 2024 – 2029 TERM**

- Number of additional members of the BOD to be elected (expected): 01 member.
- Term of the additional member: The remaining duration of the 2024–2029 term.
- Structure of the Board of Directors:

The structure of the Board of Directors must ensure that at least one-third (1/3) of the total number of Board members are non-executive members (i.e., members of the Board of Directors who are not the General Director, Deputy General Directors, Chief Accountant, or other executive managers as defined by the Company's Charter).

The number of independent member of the Board of Directors must be at least 01 member.

II. CRITERIA AND CONDITIONS FOR NOMINATION AND SELF-NOMINATION OF MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2024 - 2029 TERM

1. Criteria and Conditions for Member of the Board of Directors (Pursuant to Article 155 of the Law on Enterprises and Article 7 of the Regulation on Operations of the Board of Directors)

- a. Must not fall under the prohibitions specified in Clause 2, Article 17 of the Law on Enterprises;
- b. Must possess professional qualifications and experience in business administration or in the company's business sector or industry, and are not necessarily required to be shareholders of the company;
- c. A member of the Board of Directors may concurrently serve on the Board of Directors of other companies but shall not simultaneously serve as a board member of more than five (05) other companies.

2. Criteria for Independent Members of the Board of Directors (Pursuant to Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulation on Operations of the Board of Directors)

An independent member of the Board of Directors must meet the following criteria and conditions:

- a. Is not currently working for the company and has not worked for the company for at least the past three (03) consecutive years;
- b. Is not currently receiving salaries or remuneration from the company, except for allowances to which members of the Board of Directors are entitled under regulations;
- c. Is not a spouse, biological parent, adoptive parent, biological child, adopted child, biological sibling of any major shareholder of the company or of any manager of the company;
- d. Does not directly or indirectly own at least one percent (01%) of the total voting shares of the company;
- e. Has not previously served as a member of the Board of Directors or the Board of Supervisors of the company for at least five (05) consecutive years, unless having been consecutively appointed for two (02) terms.

3. Nomination and Candidacy of Candidates for the Board of Directors (Pursuant to Clause 5, Article 115 of the Law on Enterprises and Article 28 of the Company's Charter)

- a. A shareholder or group of shareholders holding from 5% to less than 10% of the total voting shares may nominate one (01) candidate;



- b. A shareholder or group of shareholders holding from 10% to less than 30% of the total voting shares may nominate up to two (02) candidates;
- c. A shareholder or group of shareholders holding from 30% to less than 40% of the total voting shares may nominate up to three (03) candidates;
- d. A shareholder or group of shareholders holding from 40% to less than 50% of the total voting shares may nominate up to four (04) candidates;
- e. A shareholder or group of shareholders holding from 50% to less than 60% of the total voting shares may nominate up to five (05) candidates;
- f. A shareholder or group of shareholders holding from 60% to less than 70% of the total voting shares may nominate up to six (06) candidates;
- g. A shareholder or group of shareholders holding from 70% to less than 80% of the total voting shares may nominate up to seven (07) candidates;
- h. A shareholder or group of shareholders holding from 80% to less than 90% of the total voting shares may nominate up to eight (08) candidates.
- i. In the event that the number of candidates for the Board of Directors nominated and self-nominated remains insufficient, the incumbent Board of Directors may nominate additional candidates or organize nominations in accordance with a mechanism specified in the Company's internal corporate governance regulations. This nomination mechanism or the procedure for nomination by the incumbent Board of Directors must be clearly disclosed and must be approved by the General Meeting of Shareholders prior to its implementation.

III. NOMINATION AND SELF-NOMINATION DOCUMENTS:

Shareholders or groups of shareholders holding the required percentage as stipulated above, when nominating or applying as candidates for the Board of Directors of the Company, must submit the following documents to the Company either in person or by postal mail:

- Self-Nomination or nomination letter for candidacy to the Board of Directors (using the attached form);
- Information disclosure form (using the attached form);
- Copies of the candidate's legal identification documents;
- Minutes of the shareholders' group meeting (in case a group of shareholders aggregates voting shares to nominate a Board member) (using the attached form);
- Certified copies of relevant academic qualifications (if any) of the candidate/nominee.

IV. DEADLINE AND ADDRESS FOR SUBMISSION OF SELF-NOMINATION/ NOMINATION DOCUMENTS



To facilitate the organization and preparation of election materials, the Company respectfully requests that shareholders or groups of shareholders who meet the eligibility criteria for self-nomination/nomination fax the self-nomination and nomination documents as specified in Section IV above to the Company no later than 4:30 PM on June 19th, 2025. The original documents (if not yet submitted to the Company by direct delivery or postal mail) must be submitted in person to the Organizing Committee during registration for the General Meeting on June 30, 2025:

- Contact Address: Mediplantex National Pharmaceutical Joint Stock Company – 358 Giai Phong Street, Thanh Xuan District, Hanoi.
- Contact Person: Ms. Chu Huyen Trang – Position: Company Secretary.
- Tel: 024.38643360 Fax: 024.38641584.
- Email: trang.chuh@mediplantex.com.

In the event that a shareholder or group of shareholders fails to submit the original copies of the self-nomination/nomination documents as stipulated in Section IV above to the Company prior to the approval of the list of nominees/candidates at the General Meeting, such self-nomination/nomination shall be deemed non-compliant with the provisions of the Law on Enterprises and the Company's Charter, and consequently, the self-nomination/nomination shall be considered invalid at the General Meeting.

Based on the self-nomination/nomination dossiers submitted by shareholders or groups of shareholders and the accompanying documents of the candidates, the Board of Directors shall compile and approve the list of qualified candidates in accordance with regulations and submit it to the General Meeting of Shareholders for election to the Board of Directors.

In the event that, as of the date immediately preceding the opening of the General Meeting, the number of candidates nominated or self-nominated for the Board of Directors is fewer than the number of members to be elected, the remaining candidates shall be nominated by the incumbent Board of Directors or through a nomination process organized in accordance with the provisions of law and the Company's Charter.

ON BEHALF OF THE BOARD OF DIRECTORS

Thai Khac Minh

**NOMINATION LETTER
FOR MEMBER OF THE BOARD OF DIRECTORS
IN 2024 – 2029 TERM**

To: *Mediplantex National Pharmaceutical Joint Stock Company*

Shareholder's Full Name:
Citizen ID/Passport/Business Registration No:.....
Date of Issue: Place of Issue:
Legal Representative (if applicable):
Currently holding: shares.
Equivalent to% of the total voting shares.

I hereby respectfully propose that Mediplantex National Pharmaceutical Joint Stock Company allow me/ my company to nominate:

Mr./Ms.:
Citizen ID/Passport No.: Date of Issue:Place of Issue:.....
Permanent Address:
Educational Qualification: Major:
Currently holding: shares.
Equivalent to the total nominal value of: VND

To be a candidate for the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company for the remaining term of 2024–2029.

I hereby certify that the information provided above is accurate, and I take full responsibility before the law and before the General Meeting of Shareholders for the authenticity and accuracy of the enclosed documents.

Sincerely.

Enclosed Documents:

- A valid copy of Citizen ID/Passport;
- Copies of academic degrees/certificates;
- Curriculum vitae of the nominee;

....., dated 2025

Nominator

(Signature, full name, and affix seal – if applicable)

SELF-NOMINATION LETTER
MEMBER OF THE BOARD OF DIRECTORS
IN 2024 – 2029 TERM

To: Mediplantex National Pharmaceutical Joint Stock Company

My name is:.....

Citizen ID/Passport/Business Registration No:.....

Date of Issue: Place of Issue:

Permanent Address:

Educational Qualification:

Major:.....

Currently holding: shares.

Equivalent to% of the total voting shares.

I respectfully request Mediplantex National Pharmaceutical Joint Stock Company to allow me to self-nominate as a candidate for the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company.

If entrusted and elected by the shareholders as a member of the Board of Directors, I pledge to devote my full capabilities and dedication to contributing to the development of Mediplantex National Pharmaceutical Joint Stock Company.

I hereby affirm that all the information I have provided is accurate, and I shall bear full responsibility before the law and the General Meeting of Shareholders for the truthfulness and accuracy of the documents submitted.

Sincerely thanks.

Enclosed Documents:

- A valid copy of Citizen ID/Passport;
- Copies of academic degrees/certificates;
- Curriculum vitae of the nominee;

..... 2025

Candidate

(Signature, full name, and affix seal – if applicable)

Date of Issue:Place of Issue:.....

Permanent Address:

Educational Qualification: Major:.....

Enclosed Documents:

- A valid copy of Citizen ID/Passport;
- Copies of academic degrees/certificates;
- Curriculum vitae of the nominee;

Simultaneously, we unanimously appoint:

Mr./Ms.:

Identification Number (Citizen ID/Passport):

Date of Issue: Place of Issue:

Permanent Address:

to act as the representative of the group to carry out the nomination procedures in accordance with the Company's regulations on participation in nominating candidates for the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company.

This minute is made at hour on the day of month year at

We hereby certify that the information provided is true and accept full responsibility regarding the accuracy and honesty of the attached documents before the Company’s General Meeting of Shareholders and under applicable laws.

....., dated.....

SHAREHOLDER
(Nominee – Representative of the Group)
(Signature and full name)¹

¹For Institutional Shareholders:

- The legal representative shall sign and affix the official seal; or
- In case the institution appoints a capital contribution representative (authorized representative), the appointed representative shall sign and enclose the relevant appointment documents in accordance with applicable regulations.

4 x 6
 Photograph
 (most
 recent
 photo)

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

CURRICULUM VITAE

(For individuals self-nominating or nominated for election as a member of the Board of Directors)

1. Full name: Gender: Male/Female
2. Date of birth: Place of birth:
3. Nationality:
4. Citizen ID/Passport number: Issued on:/...../..... at:
5. Permanent address:
6. Contact number: Email:
7. Educational background:
8. Professional qualification:
9. Work experience:

Period	Employment History, Occupation, and Positions Held <i>(Job title, workplace)</i>	Note

10. Current position at Mediplantex National Pharmaceutical Joint Stock Company (if applicable):

11. Other positions currently held at other organizations:

Company Name	Address	Business Registration Certificate	Date/Place of Issue	Position	Shareholding/Capital Contribution Ratio

12. Number of shares held (as of the record date) at Mediplantex National Pharmaceutical Joint Stock Company: shares, accounting for..... % of charter capital, including:

- + Representing ownership of (name of the organization as State/strategic shareholder/other entity):

- + Individually owned:

13. Shareholding commitments (if any):

14. List of related persons of the declarant * :

15. Related interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):

.....
.....
.....

16. Conflicting interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):

.....
.....
.....

17. Conflicting interests with Mediplantex National Pharmaceutical Joint Stock Company (if any):

.....
.....
.....

I hereby certify that the above statements are completely accurate. I shall bear full legal responsibility for any false or misleading declarations.

**CONFIRMATION BY LOCAL
AUTHORITIES OR EMPLOYING
ORGANIZATION (IF NECESSARY)**

DECLARANT
(Signature and full name)

* Related persons as defined in Clause 23, Article 4 of the Law on Enterprises 2020, and Clause 46, Article 4 of the Law on Securities 2019.